Highest-materiality recent filing
Celadon affiliate to acquire substantially all of Senti's business and pipeline via merger; Senti to remain public with streamlined structure.
Senti Biosciences issues $10M convertible notes to Celadon; discloses potential merger with $60M CVR
$10M senior secured convertible notes sold to Celadon Partners; maturity 6 months, 12% default interest rate on event of default.
Net loss $4.2M ($0.14/share) vs $14.1M year ago; cash $8.9M as of March 31, 2026.
Senti Biosciences enters $40M convertible note agreement with Celadon; initial $10M tranche
Celadon Partners, largest stockholder, commits up to $40M via Senior Secured Convertible Notes; first tranche $10M.
Senti Biosciences completes holding company reorganization; shares convert 1:1 to new parent SNTI
Senti Biosciences Holdings becomes new public parent; each share of old common stock converted 1:1 into new common stock.
Senti Biosciences to form holding company via tax-free merger; stock to trade as SNTI
Holding company reorganization effective April 16, 2026 via merger into Senti Biosciences Holdings.
Senti Bio FY2025 net loss $61.4M; SENTI-202 gets RMAT, Phase 1 data encouraging
Net loss $61.4M for FY2025 ($2.73/share); Q4 loss $14.5M ($0.53/share).
Senti Biosciences cuts leased space 50% to 45,955 sq ft, amends sublease with GeneFab
Leased premises reduced from ~91,910 to ~45,955 rentable sq ft effective Sept 1, 2025.
Senti Bio reports SENTI-202 Phase 1 data: 50% ORR, 42% CR/CRh at RP2D; receives FDA RMAT designation
In 18 evaluable R/R AML patients, SENTI-202 achieved 50% ORR and 42% CR/CRh at RP2D; 100% of CRs MRD negative and median duration of CR 7.6 months.
Senti Bio Q3 net loss $18.1M; cash $12.2M; ASH data ahead
Cash and cash equivalents $12.2M as of Sep 30, 2025, down from $48.3M at Dec 31, 2024.
Senti Bio Q2 2025 net loss $14.7M; completes dose finding for SENTI-202 AML trial, RP2D confirmed
Net loss of $14.7M ($0.56 per share); cash $21.6M as of June 30, 2025, down from $48.3M at Dec 31, 2024.
Senti Bio appoints Bryan Baum to Board of Directors
Bryan Baum, co-founder and managing partner of K5 Global, appointed to board effective July 18, 2025.
Senti Biosciences stockholders elect three Class III directors and ratify KPMG as auditor
Brenda Cooperstone, James Collins, and Feng Hsiung elected as Class III directors to serve until 2028 annual meeting.
Senti Bio receives FDA Orphan Drug Designation for SENTI-202 CAR NK therapy in AML
FDA granted Orphan Drug Designation to SENTI-202 for relapsed/refractory hematologic malignancies, including AML.
Senti Bio reports Q1 2025 net loss $14.1M; SENTI-202 Phase 1 shows 4 of 7 cCR with MRD negativity
Net loss of $14.1M ($1.41 per share) for Q1 2025; cash and equivalents $33.8M as of March 31.
SENTI-202 Phase 1 shows 5/7 ORR in R/R AML; RP2D set; cash $33.8M at Q1 2025
5 of 7 evaluable R/R AML patients achieved ORR (3 CR, 1 CRh, 1 MLFS); all cCR patients MRD-negative.
Filed Form S-3 to register up to $300M of common stock, preferred, debt, warrants, and units.
Senti Bio reports Q4 net loss $0.6M; two AML patients remain in remission from SENTI-202 trial
Q4 net loss $0.6M ($0.67/share); full year net loss $52.8M ($12.03/share).
Feng Hsiung appointed to board as Class III director effective March 7, 2025; also joins audit committee.
Senti Biosciences stockholders approve share issuance and amended equity plan
Approved issuance of common stock upon conversion of Series A preferred and exercise of warrants (2,442,111 for, 125,063 against).
Senti Bio appoints Jay Cross as CFO and Faraz Siddiqui as SVP Technical Operations
Jay Cross appointed CFO effective March 3, 2025; base salary $465k, annual target bonus 40%, sign-on bonus $50k repayable if leaving before 14 months.
Senti Biosciences CFO Yvonne Li departs; transition consultant through March 31
Yvonne Li's consulting agreement as Interim CFO expired Jan 31, 2025; she ceased as principal financial and accounting officer.
Senti Bio secures additional $11.5M from PIPE closing and CIRM grant; cash runway into 2026
Closed subsequent PIPE closing with Celadon Partners for additional ~$10M gross proceeds (4,444 Series A shares + warrants for 6,666,000 common shares); total PIPE now $47.6M.
Senti Bio doses first patient in SN301A CAR-NK trial for liver cancer in China
First patient dosed in SN301A pilot trial for advanced GPC3-expressing HCC in mainland China.
Initial clinical data from Phase 1 trial of SENTI-202 made available in slide presentation deck.
Senti Bio reports 2 of 3 AML patients achieve MRD-negative CR in Phase 1 SENTI-202 trial
Two of three R/R AML patients at lowest dose (1.0B CAR+ NK cells) achieved CR with MRD negativity; both maintain remission (4+ and 3+ months).
Senti Biosciences raises up to $47.6M in Series A preferred stock and warrants private placement
Issued up to 21,157 shares of Series A Convertible Preferred at $2,250/share, with warrants for up to 31.7M common shares at $2.30.
Senti Bio Q3 net loss $28.9M; cash $10.5M; SENTI-202 data expected Q4 2024
Net loss $28.9M ($6.31 per share); R&D spend $8.7M (down from $9.1M YoY).
Senti Bio receives Nasdaq deficiency notice for audit committee composition
On Oct 22, 2024, Nasdaq notified Senti Bio that its audit committee has only two members, violating Listing Rule 5605(c)(2)(A).
Senti subleases 7,247 RSF of HQ to BKPBIOTECH/JLSA2 Therapeutics
Sublease of 7,247 rentable sq ft on first floor at Two Corporate Drive, South San Francisco.
Senti Bio Q2 net loss $11.2M; doses first patients in Phase 1 AML trial
Net loss of $11.2M ($2.45 per share) for Q2 2024; cash and equivalents $15.9M.
Senti Biosciences effectuates 1-for-10 reverse stock split effective July 17, 2024
Reverse stock split at 1-for-10 ratio approved by Board on July 10, 2024.
Entered amended ChEF purchase agreement with Chardan Capital Markets for existing $50M equity facility.
Stockholders approved an officer exculpation amendment limiting liability of certain officers as permitted by Delaware law; effective July 10, 2024.
Senti Bio appoints Kanya Rajangam as President; CEO Lu remains CEO
Tim Lu stepped down as President effective May 14, 2024, but continues as CEO.
Senti Bio Q1 net loss $12.1M; SENTI-202 patient dosing on track for Q2 2024
Cash and equivalents $23.7M at March 31, 2024; additional $18.9M receivable from GeneFab.
Senti Biosciences appoints Yvonne Li Interim CFO; CEO Lu named interim PFO
Timothy Lu, CEO/President, becomes interim principal financial & accounting officer effective May 4, 2024.
Senti Bio CFO Deborah Knobelman resigns; search for interim CFO underway
Deborah Knobelman, Ph.D., CFO, Treasurer and Head of Corp. Dev., resigned effective May 3, 2024.
Net loss for FY2023 was $71.1M ($1.60/share) vs $58.2M in FY2022.
Senti Biosciences Transfers to Nasdaq Capital Market, Gets Second Compliance Period
On Jan 23, 2024, Nasdaq approved transfer of Senti Biosciences common stock from Global Market to Capital Market, effective Jan 25.
Senti Bio cuts workforce 37%, extends cash runway to Q1 2025; focuses on SENTI-202
Workforce reduction of ~37% with one-time severance costs of ~$1M in Q1 2024.
Senti Bio receives FDA IND clearance for SENTI-202 CAR-NK therapy for AML
FDA cleared IND for SENTI-202, an off-the-shelf CAR-NK cell therapy targeting CD33/FLT3 hematologic malignancies including AML.
Senti Bio Q3 net loss $14.9M; cash $39.4M; Celest partnership up to $156M
Net loss $14.9M ($0.34/share) includes non-recurring $21.7M gain and $25.7M impairment from GeneFab transaction.
Senti Bio partners with Celest for SENTI-301A development in China; up to $156M milestones
Celest to lead clinical development and manufacturing of SENTI-301A in mainland China; first patient expected 1H 2024.
Senti Bio receives Nasdaq deficiency notice for bid price below $1.00 per share
Received Nasdaq notice on Aug 7, 2023 for bid price below $1.00 for 30 consecutive days.
Senti Bio extends cash runway into Q4 2024 via GeneFab deal, Q2 net loss $18.7M
GeneFab transaction provides up to $38M in cash by end of 2025; extends cash runway into Q4 2024.
Senti Bio sells manufacturing assets to GeneFab for ~$38M cash; extends cash runway to Q4 2024
Sold Alameda cGMP facility and CMC capabilities to GeneFab (backed by Celadon Partners) for ~$38M cash with deferred payments, plus $8M manufacturing credit.
Senti Biosciences stockholders elect three Class I directors and ratify KPMG at 2023 annual meeting
Timothy Lu, M.D., Ph.D. elected with 32.3M votes for; Edward Mathers elected with 22.5M for; Omid Farokhzad, M.D. elected with 26.2M for.
Senti Bio reports Q1 net loss $18.7M; cash $76.1M; SENTI-202 IND on track for 2H 2023
Net loss of $18.7M ($0.42 per share) vs $11.8M loss in Q1 2022; revenue $1.3M.
Director David R. Epstein resigns from Senti board effective June 16, 2023
David R. Epstein resigned as director and from all board committees, effective June 16, 2023.
On March 7, 2025, the Board of Directors (the “Board”) of Senti Biosciences, Inc. (the “Company”) approved the appointment of Feng Hsiung to the Board, pursuant to the terms of a letter agreement dated as of December 2, 2024, by and between the Company and Celadon Partners SPV 24.
Jay Cross was appointed as the Company’s Chief Financial Officer, effective as of March 3, 2025.
On January 31, 2025, Yvonne Li, the Consulting Agreement by and between Senti Biosciences, Inc. (the “Company”) and Yvonne Li, the Company’s Interim Chief Financial Officer, expired in accordance with its terms.
On December 2, 2024, upon the recommendation of its Nominating and Corporate Governance Committee, the Board unanimously appointed Frances D. Schulz to fill a newly created vacancy on the Board resulting from the resignation of Dr. Farokhzad, such appointment to be effective upon the initial closing of the Offering.
On November 25, 2024, Omid Farokhzad, M.D., a member of the Board and the Audit Committee of the Board, notified the Board of his resignation as a director of the Company and all committees thereof, effective November 25, 2024.
Kanya Rajangam, M.D., Ph.D., the Company's Head of Research and Development, and Chief Medical Officer, was appointed to serve as the President of the Company, effective as of May 14, 2024
Timothy Lu, M.D., Ph.D., Chief Executive Officer and President, stepped down as President
Yvonne Li was appointed as Interim Chief Financial Officer and will assume the duties of the Chief Financial Officer, effective May 4, 2024
Timothy Lu, M.D., Ph.D., the Chief Executive Officer and President of the Company, was appointed to serve as the interim principal financial officer and principal accounting officer of the Company, effective as of May 4, 2024
On April 23, 2024, Deborah Knobelman, Ph.D., the Chief Financial Officer, Treasurer and Head of Corporate Development of Senti Biosciences Inc. (“the Company”) and its principal financial officer and principal accounting officer, notified the Company of her decision to resign from her employment with the Company, effective May 3, 2024.
On August 7, 2023, Philip Lee, Ph.D., the Company’s Chief Technology Officer, notified the Company of his resignation as an employee and as Chief Technology Officer of the Company, effective on August 7, 2023, to join GeneFab as its Chief Executive Officer.
Mr. David R. Epstein, informed the board of directors (the “Board”) of Senti Biosciences, Inc. (“Senti”) of his intention to resign as a director of Senti, including resignation from all the committees of the Board on which he serves, effective as of the close of business on June 16, 2023.
Max materiality 0.85 · Median 0.65 · Most common event other_material